IS6413A - Substituted 8-arquinoline phosphodiesterase-4 inhibitors - Google Patents

Substituted 8-arquinoline phosphodiesterase-4 inhibitors

Info

Publication number
IS6413A
IS6413A IS6413A IS6413A IS6413A IS 6413 A IS6413 A IS 6413A IS 6413 A IS6413 A IS 6413A IS 6413 A IS6413 A IS 6413A IS 6413 A IS6413 A IS 6413A
Authority
IS
Iceland
Prior art keywords
arquinoline
phosphodiesterase
inhibitors
substituted
arquinoline phosphodiesterase
Prior art date
Application number
IS6413A
Other languages
Icelandic (is)
Inventor
Deschenes Denis
Dube Daniel
Gallant Michel
Girard Yves
Lacombe Patrick
Macdonald Dwight
Mastracchio Anthony
Perrier Helene
Original Assignee
Merck Frosst Canada Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd. filed Critical Merck Frosst Canada Ltd.
Publication of IS6413A publication Critical patent/IS6413A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6413A 1999-12-22 2002-06-11 Substituted 8-arquinoline phosphodiesterase-4 inhibitors IS6413A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17152299P 1999-12-22 1999-12-22
PCT/CA2000/001559 WO2001046151A1 (en) 1999-12-22 2000-12-20 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors

Publications (1)

Publication Number Publication Date
IS6413A true IS6413A (en) 2002-06-11

Family

ID=22624050

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6413A IS6413A (en) 1999-12-22 2002-06-11 Substituted 8-arquinoline phosphodiesterase-4 inhibitors

Country Status (32)

Country Link
EP (1) EP1244628A1 (en)
JP (1) JP3782011B2 (en)
KR (1) KR20020082839A (en)
CN (1) CN1221534C (en)
AR (1) AR029214A1 (en)
AU (1) AU778531B2 (en)
BG (1) BG65403B1 (en)
BR (1) BR0016651A (en)
CA (1) CA2393749C (en)
CO (1) CO5261613A1 (en)
CZ (1) CZ20022171A3 (en)
DZ (1) DZ3244A1 (en)
EA (1) EA004747B1 (en)
EE (1) EE200200342A (en)
GE (1) GEP20053626B (en)
HK (1) HK1057560A1 (en)
HR (1) HRP20020545A2 (en)
HU (1) HUP0203896A3 (en)
IL (1) IL150114A0 (en)
IS (1) IS6413A (en)
MX (1) MXPA02006329A (en)
MY (1) MY134008A (en)
NO (1) NO20023013L (en)
NZ (1) NZ520258A (en)
PE (1) PE20010989A1 (en)
PL (1) PL355752A1 (en)
SK (1) SK8972002A3 (en)
TW (1) TWI280240B (en)
UA (1) UA74815C2 (en)
WO (1) WO2001046151A1 (en)
YU (1) YU47102A (en)
ZA (1) ZA200204862B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10110772A1 (en) * 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and PDE-IV inhibitors
EA005864B1 (en) * 2000-12-20 2005-06-30 Мерк Энд Ко., Инк. Process for making substituted 8-arylquinolinium benzenesulfonate
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
DE60204463T2 (en) 2001-06-27 2006-05-18 Merck Frosst Canada & Co, Kirkland Substituted 8-arylquinolines as PDE4 inhibitors
US7009055B2 (en) * 2001-07-24 2006-03-07 Merck & Co., Inc. Preparation of Sulfonyl quinoline
PL205927B1 (en) * 2001-09-19 2010-06-30 Nycomed Gmbh Combination of a pde inhibitor and a leukotriene receptor antagonist
ATE432261T1 (en) * 2002-03-18 2009-06-15 Merck Frosst Canada Ltd PDE4 INHIBITORS WITH HETEROBIDGE SUBSTITUTED 8-ARYLCINOLINE
NZ542407A (en) * 2003-03-05 2008-08-29 Celgene Corp Diphenylethylene compounds and uses thereof
JP2007530594A (en) * 2004-03-25 2007-11-01 シンタ ファーマシューティカルズ コーポレーション Acrylonitrile derivatives for use in inflammation and immunity related applications
JP2008545389A (en) * 2005-05-19 2008-12-18 シナージェンズ バイオサイエンス リミティド Methods and compositions for assessment of lung function and lung injury
RS53461B (en) 2006-07-05 2014-12-31 Takeda Gmbh Combination of hmg-coa reductase inhibitors atorvastatin or simvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast for the treatment of inflammatory pulmonary diseases
MX2009000148A (en) * 2006-07-07 2009-10-26 Kalypsys Inc Bicyclic heteroaryl inhibitors of pde4.
US20080103105A1 (en) * 2006-09-22 2008-05-01 Braincells, Inc. HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
WO2008099210A2 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2533780B1 (en) 2010-02-12 2017-08-23 AskAt Inc. 5-ht4 receptor agonists for the treatment of dementia
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20140328893A1 (en) 2011-10-11 2014-11-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nutlin compounds for use in the treatment of pulmonary hypertension
JP2020532551A (en) * 2017-09-03 2020-11-12 アンジオン バイオメディカ コーポレーション Vinyl heterocycle as a Rho-related coiled coil kinase (ROCK) inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
JPH11209350A (en) * 1998-01-26 1999-08-03 Eisai Co Ltd Nitrogen-containing heterocyclic derivative and medicine containing the same

Also Published As

Publication number Publication date
YU47102A (en) 2005-06-10
BG65403B1 (en) 2008-06-30
TWI280240B (en) 2007-05-01
NO20023013D0 (en) 2002-06-21
HUP0203896A2 (en) 2003-04-28
EE200200342A (en) 2003-06-16
GEP20053626B (en) 2005-10-10
AR029214A1 (en) 2003-06-18
BG106840A (en) 2003-01-31
CN1221534C (en) 2005-10-05
CA2393749A1 (en) 2001-06-28
EA200200702A1 (en) 2003-02-27
AU778531B2 (en) 2004-12-09
NO20023013L (en) 2002-08-22
EP1244628A1 (en) 2002-10-02
AU2336201A (en) 2001-07-03
PL355752A1 (en) 2004-05-17
JP3782011B2 (en) 2006-06-07
HUP0203896A3 (en) 2003-05-28
SK8972002A3 (en) 2002-11-06
MY134008A (en) 2007-11-30
BR0016651A (en) 2002-09-10
UA74815C2 (en) 2006-02-15
JP2003531112A (en) 2003-10-21
DZ3244A1 (en) 2001-06-28
ZA200204862B (en) 2003-03-17
MXPA02006329A (en) 2004-05-14
CN1434801A (en) 2003-08-06
NZ520258A (en) 2004-05-28
KR20020082839A (en) 2002-10-31
CO5261613A1 (en) 2003-03-31
PE20010989A1 (en) 2001-10-01
HK1057560A1 (en) 2004-04-08
EA004747B1 (en) 2004-08-26
CA2393749C (en) 2008-06-17
WO2001046151A1 (en) 2001-06-28
CZ20022171A3 (en) 2002-11-13
IL150114A0 (en) 2002-12-01
HRP20020545A2 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
PT1181017E (en) METALOPROTEASE INHIBITORS
NO20041293L (en) Alkyne-aryl phosphodiesterase-4 inhibitors
PT1224195E (en) TGLS2 INHIBITOR C-ARYL-GLYCOSIDES
CY2012026I2 (en) QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS
NO20016115L (en) Substituted heterocycle-condensed gamma-carboline
PT1224180E (en) SUBSTITUTED AZOIS
EE200100502A (en) Compounds
PT1194404E (en) ASPARTIL-PROTEASE INHIBITORS
NO20023013L (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
NO990431D0 (en) Golfk ° llehode
NO20014243D0 (en) Dihetero-substituted metalloprotease inhibitors
NO20032807D0 (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
NO20021658D0 (en) asphalt inhibitors
ID29533A (en) CALSILITIC COMPOUNDS
NO20025659L (en) Heterocyclic compounds
NO20020466D0 (en) Calcilitic compounds
DE60009260D1 (en) THIOPYRANDERIVATE AS MMP INHIBITORS
NO20022927D0 (en) Substituted pyrrazoles
NO20014262D0 (en) Tiazoloindolinon compounds
DE50003921D1 (en) SUBSTITUTED PHENYLURACILE
ID29984A (en) BIS-STIRILBIFENIL COMPOUNDS
ID30507A (en) DIARILAMINA SUBSTITUTED 1-HETEROSICLUS
NO993072D0 (en) Horra ° r
NO992685D0 (en) Scaffold-l ° pekatt